Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(4):554–558. doi: 10.1038/bjc.1997.97

Oestrogen increases S-phase fraction and oestrogen and progesterone receptors in human cervical cancer in vivo.

D Bhattacharya 1, A Redkar 1, I Mittra 1, U Sutaria 1, K D MacRae 1
PMCID: PMC2063290  PMID: 9052410

Abstract

Although cancer of the cervix is traditionally considered not to be responsive to steroid hormones, an in vitro study has reported that the addition of oestrogen increased cellular proliferation in a cervix cancer cell line that was inhibited by progesterone. We investigated whether the reported in vitro effects of oestrogen and progesterone on cellular proliferation can be replicated in locally advanced cervical cancer in vivo and whether these effects, if any, are related to oestrogen and progesterone receptor (ER and PgR) content of the tumour. One hundred post-menopausal patients with locally advanced cervical cancer were systematically allocated by rotation to the four treatment groups: (1) control group receiving no treatment; (2) ethinyl oestradiol 50 micrograms: (3) norethisterone 5 mg: (4) a combination of ethinyl oestradiol and norethisterone. Hormone treatment (five doses) was given orally every 12 h. Tissue biopsies were taken before and 12 h after the last hormone treatment. S-phase fraction (SpF) was measured by flow cytometry, and ER and PgR were measured by enzyme immunoassay. Results were analysed using two-factor analysis of variance, the factors being oestrogen-absent or present- and progesterone-absent or present. The main effects of oestrogen were increases in SpF, ER and PgR, which were statistically significant (P = 0.0056, 0.0009 and 0.01 respectively), indicating that there is much greater change in these three parameters in the presence of oestrogen (mean changes 7.808%, 6.258 fmol mg-1 and 12.716 fmol mg-1 for SpF, ER and PgR respectively) than in its absence (mean change -1.986%,-3.041 fmol mg-1 and 1.736 fmol mg-1 respectively). The progestogen main effect and the oestrogen-progestogen interaction were not significant. The rise in SpF, ER and PgR in the presence of oestrogen had a correlation coefficient with the initial ER values of -0.0565, -0.2863 and -0.1230 respectively, none being statistically significant, suggesting that the oestrogen actions were not strictly related to baseline ER concentrations. The combined median baseline ER and PgR values of the four groups were 1.48 fmol mg-1 and 0.80 fmol mg-1 respectively. Our results show that oestrogen is capable of increasing SpF in locally advanced cervical cancer in vivo and may help to revive interest in the use of oestrogen as a radiosensitizing agent in the treatment of this disease.

Full text

PDF
554

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bettini E., Pollio G., Santagati S., Maggi A. Estrogen receptor in rat brain: presence in the hippocampal formation. Neuroendocrinology. 1992 Oct;56(4):502–508. doi: 10.1159/000126267. [DOI] [PubMed] [Google Scholar]
  2. Ciocca D. R., Roig L. M. Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocr Rev. 1995 Feb;16(1):35–62. doi: 10.1210/edrv-16-1-35. [DOI] [PubMed] [Google Scholar]
  3. Conte P. F., Fraschini G., Alama A., Nicolin A., Corsaro E., Canavese G., Rosso R., Drewinko B. Chemotherapy following estrogen-induced expansion of the growth fraction of human breast cancer. Cancer Res. 1985 Nov;45(11 Pt 2):5926–5930. [PubMed] [Google Scholar]
  4. Fabian C. J., Kimler B. F., McKittrick R., Park C. H., Lin F., Krishnan L., Jewell W. R., Osborne C. K., Martino S., Hutchins L. F. Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancers--a Southwest Oncology Group study. Cancer Res. 1994 Oct 15;54(20):5357–5362. [PubMed] [Google Scholar]
  5. Ford L. C., Berek J. S., Lagasse L. D., Hacker N. F., Heins Y. L., DeLange R. J. Estrogen and progesterone receptor sites in malignancies of the uterine cervix, vagina, and vulva. Gynecol Oncol. 1983 Feb;15(1):27–31. doi: 10.1016/0090-8258(83)90113-0. [DOI] [PubMed] [Google Scholar]
  6. Gao Y. L., Twiggs L. B., Leung B. S., Yu W. C., Potish R. A., Okagaki T., Adcock L. L., Prem K. A. Cytoplasmic estrogen and progesterone receptors in primary cervical carcinoma: clinical and histopathologic correlates. Am J Obstet Gynecol. 1983 Jun 1;146(3):299–306. doi: 10.1016/0002-9378(83)90752-4. [DOI] [PubMed] [Google Scholar]
  7. Horwitz K. B., McGuire W. L. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem. 1978 Apr 10;253(7):2223–2228. [PubMed] [Google Scholar]
  8. Hunter R. E., Longcope C., Keough P. Steroid hormone receptors in carcinoma of the cervix. Cancer. 1987 Aug 1;60(3):392–396. doi: 10.1002/1097-0142(19870801)60:3<392::aid-cncr2820600318>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  9. Hähnel R., Martin J. D., Masters A. M., Ratajczak T., Twaddle E. Estrogen receptors and blood hormone levels in cervical carcinoma and other gynecological tumors. Gynecol Oncol. 1979 Oct;8(2):226–233. doi: 10.1016/0090-8258(79)90029-5. [DOI] [PubMed] [Google Scholar]
  10. Jensen E. V., Greene G. L., Closs L. E., DeSombre E. R., Nadji M. Receptors reconsidered: a 20-year perspective. Recent Prog Horm Res. 1982;38:1–40. doi: 10.1016/b978-0-12-571138-8.50006-8. [DOI] [PubMed] [Google Scholar]
  11. Lessey B. A., Wahawisan R., Gorell T. A. Hormonal regulation of cytoplasmic estrogen and progesterone receptors in the beagle uterus and oviduct. Mol Cell Endocrinol. 1981 Feb;21(2):171–180. doi: 10.1016/0303-7207(81)90054-x. [DOI] [PubMed] [Google Scholar]
  12. McCormack S. A., Glasser S. R. Differential response of individual uterine cell types from immature rats treated with estradiol. Endocrinology. 1980 May;106(5):1634–1649. doi: 10.1210/endo-106-5-1634. [DOI] [PubMed] [Google Scholar]
  13. Nolan C., Przywara L., Weigand R. The Abbott ER-EIA monoclonal kit. Clin Chem. 1987 Jun;33(6):1105–1108. [PubMed] [Google Scholar]
  14. Piva R., Bianchini E., Kumar V. L., Chambon P., del Senno L. Estrogen induced increase of estrogen receptor RNA in human breast cancer cells. Biochem Biophys Res Commun. 1988 Sep 15;155(2):943–949. doi: 10.1016/s0006-291x(88)80587-4. [DOI] [PubMed] [Google Scholar]
  15. Punnonen R., Lukola A. High-affinity binding of estrone, estradiol and estriol in human cervical myometrium and cervical and vaginal epithelium. J Endocrinol Invest. 1982 Jul-Aug;5(4):203–207. doi: 10.1007/BF03348324. [DOI] [PubMed] [Google Scholar]
  16. RUNGE H. [Supplementary hormone therapy of cancer]. Arch Gynakol. 1959;193:121–138. doi: 10.1007/BF00837165. [DOI] [PubMed] [Google Scholar]
  17. Soutter W. P., Pegoraro R. J., Green-Thompson R. W., Naidoo D. V., Joubert S. M., Philpott R. H. Nuclear and cytoplasmic oestrogen receptors in squamous carcinoma of the cervix. Br J Cancer. 1981 Aug;44(2):154–159. doi: 10.1038/bjc.1981.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sugimori H., Taki I., Koga K. Adjuvant hormone therapy to radiation treatment for cervical cancer. Acta Obstet Gynaecol Jpn. 1976 Apr;23(2):77–82. [PubMed] [Google Scholar]
  19. Sutherland R. L., Geynet C., Binart N., Catelli M. G., Schmelck P. H., Mester J., Lebeau M. C., Baulieu E. E. Steroid receptors and effects of oestradiol and progesterone on chick oviduct proteins. Eur J Biochem. 1980;107(1):155–164. doi: 10.1111/j.1432-1033.1980.tb04636.x. [DOI] [PubMed] [Google Scholar]
  20. Tennvall J., Wennerberg J., Willén R., Ask A., Baldetorp B., Fernö M. T3N0 glottic carcinoma: DNA S-phase as a predictor of the outcome after radiotherapy. Acta Otolaryngol. 1993 Mar;113(2):220–224. doi: 10.3109/00016489309135796. [DOI] [PubMed] [Google Scholar]
  21. Vargas Roig L. M., Lotfi H., Olcese J. E., Lo Castro G., Ciocca D. R. Effects of short-term tamoxifen administration in patients with invasive cervical carcinoma. Anticancer Res. 1993 Nov-Dec;13(6B):2457–2463. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES